- BioLineRx Ltd. is a clinical-stage biopharmaceutical company focused on developing innovative oncology and rare disease treatments.
- The company is set to release its Q1 2026 financial results on May 27, 2026, with analysts projecting an earnings per share (EPS) of -$1.04 and revenue of $343 thousand.
- Despite a negative Price-to-Earnings (P/E) ratio of -11.25, BioLineRx demonstrates solid financial health with a current ratio of 1.95 and a manageable Debt-to-Equity ratio of 0.56.
BioLineRx Ltd. (NASDAQ: BLRX) is a clinical-stage biopharmaceutical company. This means it is focused on developing new drugs that have not yet been fully approved for sale. The company’s work centers on creating treatments for oncology, which is the study and treatment of cancer, and other rare diseases.
As highlighted by PR Newswire, BioLineRx will release its financial results for the first quarter of 2026 on May 27, 2026. Following the announcement, the company plans to host a conference call for investors. This call will feature remarks from its Chief Executive Officer, Philip Serlin, to discuss the results.
For the upcoming report, Wall Street analysts estimate an earnings per share (EPS) of -$1.04. This expectation of a loss is consistent with the company’s recent performance. BioLineRx has a negative Price-to-Earnings (P/E) ratio of -11.25, which indicates the company was not profitable over the past year.
Analysts also project that revenue for the quarter will be $343 thousand. In relation to its sales, the company’s Price-to-Sales (P/S) ratio is 11.27. This metric shows that investors are currently paying over $11 for every dollar of the company’s sales, which can be common for companies in a growth phase.
Regarding its financial health, BioLineRx maintains a Debt-to-Equity ratio of 0.56, showing it has less debt than shareholder equity. The company’s liquidity appears solid with a current ratio of 1.95. A current ratio above one suggests a company can pay its short-term bills, and BioLineRx has nearly double the assets needed.
